Global Research and Evidence Lab 14 August 2024 Madrigal Pharmaceuticals Inc Rezdiffra Formulary Coverage Tracker Rezdiffra coverage substantially improves in July update (50% commercial coverage, consistent w/mgmt commentary). See inside for an overview of the data on coverage and formulary status plan by plan and how Rezdiffra coverage is changing over time. We update our proprietary monthly formulary coverage tracker for MDGL's Rezdiffra using Evidence Lab's US drug formulary monitor (access data here). ...

ab 14 August 2024 Global Research and Evidence Lab LatAm Agribusiness Agricultural Atlas: Mapping August Data Equities Americas Energy We analyse data from Conab and the USDA, which reinforce our sideways views for grain prices over the next 18 months. Soybean - US' strong crop drawing closer and headwinds for prices Brazil: Nearing the conclusion of 2023/24, Conab released steady production forecast at 147.4mn tons, which compares to MBAgro's estimates at 152.1mn tons. For 2024/25, IMEA forecasts higher ac ...

Global Research and Evidence Lab 14 August 2024 First Read Performance Food Group Company What's The Initial View On 4Q'24 Results? PFGC's 4Q'24 adj EPS $1.45 vs. UBSe $1.35; cons. $1.37; Acquiring Cheney Bros Altogether, we think PFGC's 4Q results reflect its ability to take market share, despite the increasingly challenging macro backdrop. It guided in line to slightly above where we believe market expectations were for adjusted EBITDA for FY'25 (based on our conversations with investors). Still, we belie ...

Global Research and Evidence Lab 14 August 2024 First Read Brinker International Inc Initial Thoughts on F4Q Results Strong F4Q sales beat, but disappointing flow-through; FY25 guidance mixed F4Q results included an adj EBITDA miss ($141.8MM vs Cons. $144.7MM), reflecting restaurant margin downside (15.2% vs. Cons. 15.5%) and higher stock-based compensation despite better than expected revenues ($1.21 BN vs Cons. $1.16 BN). Restaurant expenses were higher than expected (27.1% vs Cons. 26.7%) and G&A above C ...

Investment Rating - The investment rating for Cemig is Neutral with a 12-month price target of R$10.40 per share [5][6][23]. Core Insights - Cemig reported net revenue ex-construction of R$8,177 million for 2Q24, reflecting a 3% year-over-year increase, which aligns with UBS estimates and consensus [2][9]. - Adjusted EBITDA for the same period was R$1,726 million, which is 5% lower year-over-year and 4% below UBS estimates, while net income increased by 36% year-over-year to R$1,689 million, primarily due to a provision reversal of R$584 million [2][3][10]. - The company plans to ramp up capital expenditures significantly, with a guidance of R$6.2 billion for 2024, following a capex of R$1.4 billion in 2Q24 [2][3]. Financial Metrics - The volume of energy billed in the distribution business increased by 3% year-over-year, driven by a 7% increase in the residential segment and a 3% increase in the industrial segment [3]. - Consolidated costs and expenses rose by 2% year-over-year, with notable increases in personnel costs (17%) and materials and third-party services costs (11%) [3][9]. - The company announced a dividend payment of R$1.4 billion, resulting in a 4.2% dividend yield based on the last close [2][3]. Valuation and Forecast - The valuation of Cemig is based on a DCF FCFE model, with key assumptions including a long-term energy price of R$178/MWh and a cost of equity of 14.1% [5][6]. - Forecasts indicate a price appreciation of -6.3% and a dividend yield of 9.8%, leading to an expected stock return of 3.5% [11]

First Read Cardinal Health Inc First Take: Improved FY25 Guidance and LT Commitment to GMPD Conveyed Loaded Print: Improved FY25 Guide, Steady GMPD Outlook and More Aggressive Repos Should Buoy Sentiment Along with F4Q results, CAH tweaked preliminary FY25 financial expectations offered last quarter. Key guidance highlights include: (1) FY25 EPS range of $7.55-7.70 (prior: at least $7.50) on better Pharma EBIT growth of +1-3% ( prior: at least 1% - at midpoint adds ~$0.06); (2) lower interest and other (at ...

Online Games: Over August 14, 2024 Earnings Review Tencent Holdings (700 HK, BUY, TP: HK$485.00) BUY | --- | |-------------------------| | Target Price: HK$485.00 | | | | 52-Week High/Low (HK$) | | Market Cap (US$mn) | | Shares Outstanding (mn) | | 3-mth ADTV (US$mn) | | Free Float (%) | | Major Shareholder (%) | | Naspers | | Ma Huateng | | Lau Chi Ping Martin | | | | | Key Changes DiffNew Old RatingBUYBUYN/A Target Price (HK$)485.000%485.00 2024E EPS (RMB)23.1421.348% 2025E EPS (RMB)23.6622.933% 2026E EPS ...

Investment Rating - The investment rating for Viridian Therapeutics Inc. (VRDN) is "Buy" with a 12-month price target of $25.00, indicating an upside potential of 70.1% from the current price of $14.70 [9]. Core Insights - Viridian Therapeutics Inc. (VRDN) is well-positioned with its VRDN-003 product, which is expected to have best-in-class potential in the subcutaneous (SC) treatment of thyroid eye disease (TED) due to its dosing regimens and autoinjector properties [5][8]. - SLRN has refocused its pipeline strategy to prioritize lonigutamab for TED, moving directly to Phase 3 development by Q1 2025, which increases competitive pressure on VRDN-003 [2][3]. - VRDN plans to initiate Phase 3 trials for VRDN-003 in August 2024, with topline data expected in the first half of 2026, ahead of SLRN's timelines [3][5]. Summary by Sections Pipeline Strategy - SLRN has discontinued investments in HS/PsA and reduced its workforce by 33% to extend its cash runway to mid-2027, focusing solely on lonigutamab for TED [2]. - Early Phase 1/2 data for lonigutamab showed promising results, but VRDN-003's half-life extension and autoinjector features are seen as significant commercial advantages [2][5]. Clinical Development - VRDN-003's Phase 3 REVEAL-1/REVEAL-2 trials are set to begin in August 2024, with topline data expected in 1H26 and a BLA filing by the end of 2026 [3][5]. - SLRN's decision to skip Phase 2b/3 studies and move directly to Phase 3 could intensify competition, but VRDN-003 is anticipated to deliver data from its primary endpoints before SLRN [3][5]. Safety and Efficacy - Updates on tinnitus effects from SLRN's trials indicate that hearing adverse events are mostly transient and manageable, aligning with VRDN's observations [4][5]. - The Phase 3 studies for both VRDN and SLRN may reveal different occurrences of hearing adverse events due to their varying study durations [4].

Investment Rating - The report indicates a forecast of three more rate cuts in 2024 and one additional cut in 2025, leading to a terminal rate of 2.75% [4][8]. Core Insights - The Riksbank's Executive Board maintained the policy rate at 3.75% during the last meeting, with guidance suggesting potential cuts if inflation prospects remain favorable [4]. - Recent inflation data shows that July core inflation was 2.2% year-over-year, aligning with Riksbank's projections, while the activity picture remains subdued with a Q2 GDP decline of -0.8% quarter-over-quarter [5][7]. - The report anticipates a 25 basis point cut to 3.5% in the upcoming meeting, with expectations for further cuts in August, September, and November [8]. Summary by Sections Monetary Policy Outlook - The Riksbank's policy rate is projected to decrease to 3.33% in Q4 2024 and 2.94% in Q2 2025, reflecting a cautious approach due to global developments and economic activity slowdown [4]. - The majority of the Executive Board members are open to delivering three more rate cuts this year, citing favorable inflation prospects and a slowing economy [4]. Inflation Trends - Core inflation metrics have shown mixed progress, with July's core inflation at 2.2% year-over-year and a sequential increase of 0.37% month-over-month [5][6]. - The trade-weighted krona has remained stable since the June meeting, indicating a lack of significant volatility [6]. Economic Activity - The economic activity remains subdued, with a flash GDP print of -0.8% quarter-over-quarter for Q2, following a growth of 0.7% in Q1 [7]. - Unemployment rates have stabilized at 8.2%, and consumer confidence has shown signs of improvement, suggesting potential for economic recovery in Q3 [7].

Investment Rating - The report does not explicitly provide an investment rating for the Polish inflation outlook but indicates a more dovish long-term outlook compared to the National Bank of Poland (NBP) [3]. Core Insights - The final July inflation estimate confirmed a rise from +2.6% year-on-year (yoy) in June to +4.2% yoy in July, primarily driven by higher utility inflation, which increased from -1.6% yoy in June to +10.1% yoy in July due to the partial expiry of energy price shields [2][4]. - Food inflation also rose for the third consecutive month, from +2.5% yoy to +3.2% yoy in July, while core inflation slightly increased from +3.6% yoy to +3.8% yoy [2][4]. - The report forecasts lower-than-expected Polish inflation in the medium term, attributing this to external factors, the recent appreciation of the zloty, and favorable food prices [3]. Summary by Sections Inflation Overview - July inflation rose to +4.2% yoy from +2.6% yoy in June, with a month-on-month (mom) increase of 26.2% (seasonally adjusted, annualized) [2][4]. - Core inflation increased to +3.8% yoy in July from +3.6% yoy in June, with a mom increase of 6.6% (seasonally adjusted, annualized) [4]. Key Figures - Utility inflation surged to +10.1% yoy in July from -1.6% yoy in June, while food inflation rose to +3.2% yoy from +2.5% yoy [4]. - The report highlights significant changes in various inflation components, including a dramatic increase in electricity, gas, and other fuels, which saw a yoy increase of +10.1% [4]. Long-term Outlook - The long-term outlook remains dovish, with expectations of a temporary rebound in inflation due to the expiry of energy price caps, but overall disinflation is anticipated in the second half of 2024 [3][7].